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Abstract
Cysteine cathepsins have emerged as new players in inflammatory lung disorders. Their activities are dramatically increased
in the sputum of cystic fibrosis (CF) patients, suggesting that they are involved in the pathophysiology of CF. We have
characterized the cathepsins in CF expectorations and evaluated their use as markers of colonization by Pseudomonas
aeruginosa. The concentrations of active cathepsins B, H, K, L and S were the same in P. aeruginosa-positive (19 Ps+) and P.
aeruginosa-negative (6 Ps2) samples, unlike those of human neutrophil elastase. Also the cathepsin inhibitory potential and
the cathepsins/cathepsin inhibitors imbalance remained unchanged and similar (,2-fold) in the Ps+ and Ps2 groups
(p,0.001), which correlated with the breakdown of their circulating cystatin-like inhibitors (kininogens). Procathepsins,
which may be activated autocatalytically, are a potential proteolytic reservoir. Immunoblotting and active-site labeling
identified the double-chain cathepsin B, the major cathepsin in CF sputum, as the main molecular form in both Ps+ and Ps2
samples, despite the possible release of the ,31 kDa single-chain form from procathepsin B by sputum elastase. Thus, the
hydrolytic activity of cysteine cathepsins was not correlated with bacterial colonization, indicating that cathepsins, unlike
human neutrophil elastase, are not suitable markers of P. aeruginosa infection.
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Introduction
Cystic fibrosis is an inherited life-threatening disorder. It is
associated with a mutation of the CF transmembrane glycoprotein
that is involved in the transport of chloride ions [1,2]. This
exocrinopathy mainly affects cells producing mucus, sweat and
digestive fluids and causes severe lung damage and nutritional
deficiencies. While palliative care is presently available for these
patients, there is no effective cure [3]. The clinical manifestations
of chronic inflammation of the respiratory epithelium (overpro-
duction of mucus, persistent cough, wheezing, repeated lung and
sinus infections), are mainly due to the release of proteolytic
enzymes and the disruption of the protease-antiprotease balance.
This leads to the degradation of lung tissues and the impairment of
lung function. The involvement of serine proteases released from
polymorphonuclear neutrophils (elastase, cathepsin G, protease 3)
has been extensively studied [4,5] but the role of lung cysteine
proteases (CPs, family C1) is less well documented [6]. The
cysteine cathepsins B, H, L, K and S are involved in a variety of
proteolytic processes, such as the turnover of endocytosed proteins,
prohormone processing, MHC-II antigen presentation, and
extracellular matrix and basal membrane degradation. They are
also involved in diseases like tumor metastasis, osteoporosis, and
rheumatoid arthritis [7,8]. Lung CPs are mainly produced by
macrophages, fibroblasts and epithelial cells, while cathepsin H is
mainly found in type II pneumocytes [9,10]. Stimulated
monocyte-derived macrophages can release the CPs that are
found in the bronchoalveolar lavage fluids (BALFs) of smokers
suffering from emphysema [11]. Active forms of cysteine
cathepsins are also present in BAL fluids from patients suffering
from infiltrative inflammatory disorders like sarcoidosis and
alveolar proteinosis, and silicosis [12,13,14].
The hyperviscous mucus found in CF airways severely hinders
effective phagocytosis by neutrophils and makes the lungs more
susceptible to infection by Pseudomonas aeruginosa, Staphylococcus
aureus,a n dHaemophilus influenzae.W h i l eS. aureus is predominantly
f o u n di nt h ee a r l ys t a g e so fc o l o n i z a t i o n ,P. aeruginosa is more
resistant to antibiotics and soon becomes the main organism
infecting CF lungs [15]. Cysteine cathepsins may be important in
the pathophysiology of cystic fibrosis under these conditions [16].
The activity of cathepsin B is dramatically higher (,several 100-
fold) in the bronchoalveolar lavage fluids of CF patients than in
those of healthy patients [17]. This high proteolytic activity in CF
lungs may contribute to the dysfunction of the inflammatory
response and thus to local tissue damage [16]. Cathepsins may
also exacerbate lung disease by weakening the host defenses by
breaking down and inactivating SLPI (secretory leukocyte
protease inhibitor), beta-defensins 2 and 3 (HBD-2 and HBD-
3), and lactoferrin. The resulting loss of antimicrobial activity
favors infection and colonization by opportunistic pathogens
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from CF patients whose lungs are colonized by P. aeruginosa is
higher than reported for healthy controls [18]. A recent study
detected both cathepsins B and S in CF sputum samples and
proposed their use as markers of CF airway inflammation. The
authors also suggested that the concentrations of both enzyme
were correlated not only with each other but also with those of
neutrophil elastase and IL-8 [20].
However, changes in the concentration and activity of CPs must
be carefully examined before it can be stated that CPs may be
markers of inflammation and/or bacterial infection and coloniza-
tion [21]. Thus, the primary purpose of this study was to describe
the enzymatically active forms of cysteine cathepsins in P.
aeruginosa-positive (Ps+) and P. aeruginosa-negative (Ps2)C F
expectorations using a single protocol. We then estimated the
implications of the imbalance between CPs and their specific
circulating inhibitors (kininogens, cystatins) by quantitative kinetic
analysis based on protein content rather than sputum volume (or
weight), as reported elsewhere. Finally, we analysed these data to
determine whether CP activities were correlated with P. aeruginosa
colonization and whether CPs may be useful new biological
markers.
Materials and Methods
Substrates and synthetic inhibitors
Benzyloxycarbonyl-Arg-Arg-7-amino-4-methyl coumarin (Z-
Arg-Arg-AMC), H-Arg-AMC, Z-Gly-Pro-Arg-AMC and Z-Phe-
Arg-AMC were purchased from Bachem (Weil am Rhein,
Germany) and Z-Val-Leu-Arg-AMC from Enzyme System
Products (Livermore, CA, USA), ortho-aminobenzoic acid (Abz)-
Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-(3-NO2-Tyrosine) came
from GeneCust Europe (Dudelange, Luxembourg). L-3-carboxy-
trans-2, 3-epoxy-propionyl-leucylamide-(4-guanido)-butane (E-64),
PMSF, pepstatin A, EDTA, 4-(2-Aminoethyl) benzenesulfonyl
fluoride hydrochloride (AEBSF; Pefabloc) and MMTS were from
Sigma-Aldrich (Saint-Quentin Fallavier, France). N-(4-Biphenyla-
cetyl)-S-methylcysteine-(D)-Arg-Phe-b-phenethylamide and N-(L-
3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline
(CA-074) were from Calbiochem (VWR International S.A.S.,
France). Morpholine urea-Leu- homophenylalanine-(vinylsulfo-
nyl)benzene (Mu-Leu-Hph-VSPh) was kindly provided by Dr J.H.
McKerrow (Department of Pathology, The Sandler Center for
Basic Research in Parasitic Diseases, University of California, San
Francisco, CA, USA). The biotinylated activity-based probe Biot-
LVG-CHN2 was synthesized as previously described [22]. DTT
(DL-dithiotreitol) came from Bachem. All other reagents were of
analytical grade.
Enzymes and inhibitors
Human cathepsins B, H, L and S were supplied by Calbiochem
and human neutrophil elastase by BioCentrum (Krakow, Poland).
High molecular weight kininogen (HMWK) was purchased from
Calbiochem and cystatin C from R&D Systems Europe.
Ethics Statement
Sputum samples were collected on a routine basis from adult
patients followed at the Teaching Hospital of Besanc ¸on (CHU
Jean Minjoz, France) between 2009 and 2010. Enzymatic assays
were performed in addition to routine bacteriological analyses
when the volume of sputums was sufficient for both types of tests.
Thus our protocol was considered as ‘‘waste’’ and we did not need
a specific agreement from the local research ethics committee.
CF sputum samples
Twenty five sputum samples were collected (status reported as
means 6 S.D: years, 27.1(9.4); forced expiratory volume (FEV),
2.0 (0.9) L; body mass index (BMI), 20.4 (2.8)). Very soon after
their recovery, the specimens were aseptically divided in two parts.
One half was submitted to conventional bacteriological analyses to
identify and quantify (colony-forming units per mL, cfu/mL)
bacterial pathogens [23]. Sensitivity of detection of P. aeruginosa
was $20 cfu/mL. Nineteen P. aeruginosa-positive samples and six
P. aeruginosa-negative samples used as controls were included in the
study. After thawing of the other half and to allow the accurate
handling of clinical specimens, a preservative buffer (final
concentrations: 100 mM sodium acetate, pH 5.0 plus the
peptidase inhibitors 0.5 mM PMSF, 0.5 mM EDTA, 40 mM
pepstatin A, and 1 mM MMTS) was instantly added to each CF
sputum sample before it was centrifuged at 5000 g at 4uC for
10 min. The resulting cell-free supernatants were collected,
aliquoted and frozen at 280uC. Alternatively a second buffer,
50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% NP40, 0.5 mM
EDTA, 40 mM pepstatin A, and 1 mM E-64, was used for further
analysis of elastase activity.
Immunoblotting
The goat anti-human cathepsin S was obtained from R&D
Systems. Other primary polyclonal antibodies were raised in
rabbits: anti-human cathepsin B (Calbiochem), anti-human
cathepsin L (Calbiochem), anti-human cathepsin H (Fitzgerald,
Concord, USA), anti-human cystatin C (Upstate, Lake Placid,
USA) and anti-human low molecular weight kininogen [24]. The
anti-human neutrophil elastase (HNE) was raised in rabbits using a
16-mer peptide corresponding to position 88–103 (IFEN-
GYDPVNLLNDIV) of the proelastase sequence (numbering
based on the sequence of prochymotrypsinogen [5]) coupled to
ovalbumin for immunization. The IgG fraction obtained after
ammonium sulfate precipitation was further purified by affinity
chromatography on immobilized ovalbumin. Goat anti-rabbit and
rabbit anti-goat IgG-peroxidase conjugates were supplied by
Sigma-Aldrich. Bicinchoninic acid assays were used to determine
the protein concentrations in supernatants (BCA protein assay kit,
Interchim, Montluc ¸on, France). Samples (30 mg protein) were
diluted in Laemmli buffer under reducing conditions, boiled for
5 min, separated by SDS-PAGE on 15% gels (prestained
molecular masses: Precision Plus Protein Standards, BioRad)
and electroblotted onto nitrocellulose membranes. These mem-
branes were incubated with the primary antibody (1:1000, in PBS,
0.1% Tween, 5% dried milk for 1 h at room temperature), then
with the secondary IgG-peroxidase conjugate (1:5000) for 1 h at
room temperature. Proteins were detected by chemiluminescence
(ECL Plus Western Blotting Detection system, Amersham
Biosciences, Buckinghamshire, UK). This protocol was used for
P. aeruginosa-positive (Ps+) and P. aeruginosa-negative (Ps2) samples.
Labeling cysteine cathepsins with a cystatin-derived
activity-based probe
Supernatants in buffer A (100 mM sodium acetate buffer
pH 5.5 containing 5 mM DTT, 2 mM EDTA and 0.01% Brij 35)
were incubated with a molar excess of Biot-LVG-CHN2
(cathepsin:probe, 1:300) for 1 h at 37uC, as described previously
[25]. In another set of experiments, we first incubated samples
with unlabelled inhibitors (100 mM): E-64 (a broad-spectrum
cathepsin inhibitor), CA-074 (a selective cathepsin B inhibitor) or
Mu-Leu-Hph-VSPh (a selective cathepsin S inhibitor) before
adding the biotinylated probe. Individual cathepsins B, H, L and S
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PAGE on 12% gels under reducing conditions and transferred to
nitrocellulose membranes by electroblotting. Free binding sites on
the membranes were saturated by incubation with 3% BSA in PBS
for 1 h at 37uC. The membranes were incubated with an
extravidin-peroxidase conjugate (1:2500; Sigma-Aldrich) for 2 h
at room temperature and the peroxidase activity was revealed by
chemiluminescence (ECL Plus Western Blotting Detection system).
Hydrolysis of kininogens by CF sputum
Human HMWK (1.8 mg) was incubated in 100 mM sodium
acetate buffer pH 5.5, 5 mM DTT, 2 mM EDTA, 0.01% Brij 35
with supernatant (corresponding to 10 mg protein) at 30uC for
5 hours. The mixture was then separated by 12.5% SDS-PAGE
under reducing conditions and the separated products transferred
to nitrocellulose membranes. Control mixtures contained E-64
and CA-074. HMWK hydrolysis was detected using a rabbit
polyclonal anti-kininogen antibody [24].
Enzyme activity
A panel of AMC-derived fluorogenic substrates was used to
measure the CP activities in supernatants diluted in buffer A.
Samples (final volume per well: 200 mL) in 96-well Nunc
microtiter plates (ThermoFisher Scientific, Illkirch, France) were
incubated at 37uC under gentle agitation, and their enzymatic
activities were monitored continuously at lexc=350 nm and
lem=460 nm (Gemini spectrofluorimeter, Molecular Devices,
Saint-Gre ´goire, France). The protocol for quantifying active
cathepsins in sputum supernatant was adapted from that used to
titrate the CPs in BAL fluids [12,13]. Supernatant was incubated
with concentrations of E-64 (0–100 nM) at 37uC for 30 min [26]
in buffer A and the residual endopeptidase CP activity towards Z-
Phe-Arg-AMC (20 mM) was then measured. Cathepsin B was
titrated with CA-074 (0–100 nM) using Z-Arg-Arg-AMC as
substrate (5 mM). Certain samples were incubated with CA-074
to inhibit cathepsin B before cathepsin K was titrated with E-64
using Z-Gly-Pro-Arg-AMC as substrate (50 mM), and cathepsin S
using Z-Val-Leu-Arg-AMC as substrate (20 mM). The concentra-
tion of cathepsin L was deduced from the difference between the
overall concentration of thiol-dependent endoproteases (i.e
cathepsins B+K+L+S) and the individual concentrations of
cathepsins B, K and S. The aminopeptidase activity of cathepsin
H was assayed using H-Arg-AMC (50 mM) as substrate. As
cathepsin S is more stable than the other CPs at neutral pH, its
specific activity was also assayed under mildly alkaline conditions
[27]. Supernatant was incubated in 100 mM Na-phosphate buffer
pH 7.4 (80 mL) for 1 hour at 37uC. An aliquot was then removed,
diluted with buffer A and used to measure the residual cathepsin S
activity at 37uC with Z-Val-Leu-Arg-AMC (20 mM) as the
substrate. HNE activity was measured in the supernatant (1:50)
using Abz-Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-(3-NO2-Tyr)
(10 mM) in buffer B ( 50 mM HEPES buffer pH 7.4, 150 mM
NaCl, 0.05% NP40).
Inhibitory potential of CF sputum
The procedure used to evaluate the inhibitory potential of
supernatants was adapted from Assfalg-Machleidt et al. [28]. As
most of the thiol-dependent endoprotease activities in sputum are
those of cathepsins B and L (about 80%), their CP activities were
blocked by incubating samples for 30 minutes with 0.2 mM CA-
074 and 2 mM N-(4-Biphenylacetyl)-S-methylcysteine-(D)-Arg-
Phe-b-phenethylamide. The inhibitory potential of CF sputum
was deduced by adding increasing amounts of sputum superna-
tants (0–14 mL) to E-64 titrated papain, using Z-Phe-Arg-AMC as
substrate (5 mM).
Zymogen activation in CF sputum
Diluted supernatants (20 mL, corresponding to 20 mg protein)
were incubated in 800 mL 100 mM sodium acetate buffer pH 4.3,
4 mM DTT, 10 mg/ml dextran sulfate (Sigma-Aldrich), or buffer
Ba t3 7 uC. Aliquots (2 mL) were removed at intervals (0–6 hours)
and the CP activity in them was measured at 37uC, in buffer A,
using Z-Phe-Arg-AMC (50 mM). E-64 was used as control.
Samples were analyzed in parallel by Western blotting, as
described above. Alternatively aliquots of supernatant were
incubated in 50 mM HEPES (pH 7.4), 150 mM NaCl, 0.05%
NP40 at 37uC to assay the elastase-dependent maturation of
cathepsin B, using AEBSF (Pefabloc) as control.
Statistical analyses
Results were analyzed with the non-parametric Mann–Whitney
U test; a P value,0.05 is considered to be statistically significant.
Results and Discussion
Immunodetection and labeling of cysteine cathepsins
and their inhibitors
The supernatants obtained by centrifuging the 25 Pseudomonas
aeruginosa-positive and Pseudomonas aeruginosa-negative CF sputum
samples were immediately buffered at pH 5.5 and stabilized (see
the experimental section) to preserve cysteine cathepsins from
inactivation at neutral pH and uncontrolled proteolysis. The
median protein concentration was 3.74 mg/ml with interquartile
ranges: IQR1, 3.31 mg/ml and IQR3, 4.50 mg/ml. We detected
aminopeptidase cathepsin H in all sputum supernatants in
addition to cathepsins B, L and S reported by Taggart et al.
[17] (see representative samples in Figure 1A). However the
activity profiles varied considerably, depending on the cysteine
protease studied. Cathepsin L was mostly in its proform; the
concentration of its mature form was below the limits of
immunodetection under our experimental conditions. The full
and/or partly processed proforms of cathepsin K were also
detected, but mature cathepsin K was not (data not shown; the
anti-cathepsin K antibody was a kind gift from Dr Dieter Bro ¨mme,
University of British Columbia, Vancouver, Canada). Conversely,
cathepsin H was detected mainly as its mature form. Both mature
cathepsin S and procathepsin S were found (full or partially
processed proform, depending on the sample). Mature cathepsin B
was intensely stained (mainly as its double-chain form). But the
zymogen of this most abundant and ubiquitous cathepsin was also
found. However, Martin et al. [20] did not report finding pro-
cathepsin B. This discrepancy could be due to dissimilar storage
conditions, since they diluted their expectorated sputum with an
unbuffered saline without adequate inhibitors to stabilize them.
There were small differences in the apparent molecular weights in
sputum CPs and controls that reflect their degree of glycosylation.
The enzyme/proenzyme profiles of sputum samples differed from
those of BAL fluids from patients suffering from infiltrative
inflammatory disorders [13], where cathepsins H and L were
mostly detected as mature forms and cathepsins B, K and S as
proforms. The enzyme profiles also differed from those of BAL
fluids from silicosis patients, where only the mature forms of
cathepsins B, H and L were immunodetected, while cathepsin H
was the most abundant CP [12]. However, the immunochemical
patterns of P. aeruginosa-positive and P. aeruginosa-negative samples
were fairly similar for cathepsins and their endogenous inhibitors.
Cysteine Cathepsins in Cystic Fibrosis
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inhibitors of cathepsins, have been also found in some inflamma-
tory bronchoalveolar lavage fluids and epithelial lining fluids, but
never before in CF samples (see for review: [6]). Our Western blot
analysis detected cystatin C and high and/or low molecular weight
kininogens in CF sputum (Figure 1B). Despite sputum HNE was
reported to cleave cystatin C and release a N-terminally truncated
form [29], we did not observe the presence of a shorter molecular
form of cystatin C, as also suggested by agarose electrophoresis
(data not shown). Conversely no intact but extensively degraded
kininogens were detected. Similar degradation of kininogens have
been found in other inflammatory body fluids, like synovial and
amniotic fluids, and blood plasma (for review: [30]). The lack of
undamaged kininogens together with the presence of kininogen
fragments (circa 20–40 kDa) correlates with the recent demonstra-
tion that the inability of kininogens to inhibit cathepsin B (in
contrast to cathepsins L and S) is associated with their extensive
cleavage by cathepsin B [31]. We have also shown that Biot-LVG-
CHN2, a cystatin C-derived activity-based probe, binds to sputum
cysteine cathepsins. Biot-LVG-CHN2 efficiently labeled human
cathepsins B, H, L and S (Figure 1C) by specifically targeting the
nucleophilic active site thiol. One major band was found in CF
sputum both with and without a Pseudomonas infection. This
labeling was abolished by E-64, broadly impaired by preincuba-
tion with CA-074, and to a lesser extent by Mu-Leu-Hph-VSPh.
This provides strong evidence that cathepsin B (predominant
reactive band corresponding to its double-chain form) is the most
abundant CP, and that active cathepsin S is also present in CF
sputum. Specific labeling with Biot-LVG-CHN2 also confirmed
that CPs, despite their susceptibility to thiol oxidation and the
partially defective antioxidant defenses in the lung, may retain
their enzymatic activity for some time in an oxidative environment
[32,33,34].
As both high and low molecular weight kininogens were
broken down in both Ps+ and Ps2 CF sputum (Figure 1B), we
added exogenous uncleaved HMWK to CF supernatants and
analyzed the resulting mixture. E-64 and also CA-074 partially
blocked the cleavage of exogenous HMWK (Figure 2), indicating
that cathepsins play a part in the proteolysis of kininogens by CF
sputum. Our data also confirmed that significant amounts of
cathepsins may escape regulation by their endogenous inhibitors.
This, together with the recent demonstration that the poor
inactivation of cathepsin B (unlike the tight-binding inhibition of
cathepsins L and S) by kininogens is associated with their
extensive cleavage by cathepsin B [31], indicates that cathepsin B
is a major protease involved in this process in CF sputum. This is
Figure 1. Cysteine cathepsins and their inhibitors in supernatants of CF sputum. Only representative samples are shown. (A) Proteins
(30 mg/well) were separated by 15% SDS-PAGE under reducing conditions, transferred to nitrocellulose membranes, and analyzed with polyclonal
antibodies against human cathepsins B, H, L and S. (+): Pseudomonas aeruginosa-colonized CF sputum; (2): Pseudomonas aeruginosa-negative CF
sputum.v, single-chain cathepsin B; b, double-chain cathepsin B; r, mature cathepsins S and H; w, proforms. (B) Immunostaining with polyclonal
anti-cystatin C antibody and anti-kininogen antibody. (+): Pseudomonas aeruginosa-colonized CF sputum; (2): Pseudomonas aeruginosa-negative CF
sputum. Control: Cyst, Cystatin C; HK, HMWK. Recombinant human cystatin C (R&D systems) has an additional C-terminal 10 His-tag and an apparent
molecular mass of 17 kDa, according to the supplier. (C) Supernatants of CF sputum incubated with Biot-LVG-CHN2 (30 mM), for 1 h at 37uC [25].
Other samples were pre-incubated with E-64, CA-074, and Mu-Leu-Hph-VSPh prior to adding the biotinylated activity-based probe. Samples were
separated by 12% SDS-PAGE, electroblotted and incubated with extravidin-peroxidase conjugate. The peroxidase activity was revealed by
chemiluminescence. WB: individual cathepsins B, H, L and S immunoblotted as control. Control: (2), no pre-incubation with E-64; (+), pre-incubation
with E-64 prior to adding Biot-LVG-CHN2. Sputum: E-64, pre-incubation with E-64; CA, pre-incubation with CA-074; VS, pre-incubation with Mu-Leu-
HphVSPh.
doi:10.1371/journal.pone.0025577.g001
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Quantitative analysis of sputum cysteine cathepsins and
their inhibitors
The characteristics of active proteases are expressed with
reference to the total protein concentration in CF samples and not
to volume (or dilution) of sputum supernatants in order to prevent
any bias associated with clinical specimen during sputum
collection. The BCA assays indicated that the median protein
concentration in the 25 samples tested was 3.74 mg/ml (IQR1,
3.31 mg/ml; IQR3, 4.50 mg/ml; range, 1.21–14.25 mg/ml). All
concentrations of active enzymes and inhibitors are given as
medians, with IQR1 and IQR3 values in brackets. We first
determined the specific activity of human neutrophil elastase using
the FRET substrate Abz-Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-
(3-NO2-Tyr) whose amino acid sequence is highly selective for
HNE [35]. The median values of active HNE in P. aeruginosa-
positive samples were 480.4 (261.5/552.4) nmol/g protein and
80.4 (74.9/229.4) nmol/g in P. aeruginosa-negative samples. Thus,
HNE activity in Ps+ CF sputum was significantly higher than in
the Ps-CF sputum (p-value,0.01) (Figure 3C). The increased
sputum HNE activity that is typically associated with a bacterial
infection (mainly S. aureus and P. aeruginosa) and the ensuing influx
of neutrophils agrees well with earlier reports indicating that
elastase is a valuable marker of infection for CF patients (see for
review: [36]). This is supported by the results of immunoblotting
following SDS-PAGE under reducing conditions. A polyclonal
anti-HNE antibody revealed a major band corresponding to free
unbound elastase in Ps+ CF sputum (Figure 3C), while HNE in
Ps2 CF samples was mostly as higher molecular forms that
correspond most probably to inhibitory complexes between HNE
and alpha1-protease inhibitor (a1-PI), the major serine protease
inhibitor in the lung [5]. Targeting of HNE by a1-PI obey the
suicide substrate inhibition mechanism of serpins with cleavage
within the reactive center loop of a1-PI and the formation of a 1:1
stoichiometric covalent inhibitory complex [37,38,39]. The
individual (Figure 3A) and overall (Figure 3B) concentrations of
active CF cathepsins were determined by titration (see ‘‘Material &
Methods’’ for details). The overall active cathepsins in P. aeruginosa-
positive samples was 211.5 (187.5/234.2) nmol/g, while the
activity in P. aeruginosa-negative samples was 221.7 (214.8/239.6)
nmol/g. This value is higher than that measured in silicosis
BALFs, but lower than the concentration of active CPs in BALFs
from patients with acute lung infiltrative inflammatory disorders
[6]. Cathepsin B is the most abundant cathepsin in CF sputum
(Ps+ median: 111.5 (90.4/127.9) nmol/g; Ps2 median: 112.1
(95.4/127.8) nmol/g), as suggested by immunochemical studies,
followed by the aminopeptidase cathepsin H (Ps+ median: 62.4
(21.7/103.3) nmol/g; Ps2 median: 29.5 (3.8/75.8) nmol/g) and
the endopeptidase cathepsin L (Ps+ median: 40.5 (31.8/47.4)
nmol/g; Ps2 median: 35.6 (29.7/53.3) nmol/g). The median
concentrations of cathepsin S were 19.1 (12.2/21.6) nmol/g in Ps+
sputum and 18.8 (13.3/21.6) nmol/g in Ps2 CF sputum; the
values for cathepsin K were similar: 17.7 (15.4/18.9) nmol/g in
Ps+ sputum and 17.7 (17.2/20.6) nmol/g in Ps2 CF sputum. The
differences between P. aeruginosa-positive and P. aeruginosa-negative
samples were not significant (p.0.05), including the apparent
variation in cathepsin H. We also found no correlation between
the elastase and cathepsin B activities, in contrast to the findings
for sputum from patients with bronchiectasis [29].
We assessed the residual CP inhibitory capacity (CPI, expressed
as inhibitory site equivalents) by measuring the ability of CF
sputum to inhibit E-64-titrated papain, according to Assfalg-
Machleidt et al. [28]. Again, we found no significant difference
between P. aeruginosa-positive (116 (83.8/168.2) nmol/g) and
negative (123.9 (104.7/186.6) nmol/g) samples (Figure 3B),
showing no significant difference between the two groups.
Conversely, the CP/CPI imbalance (,2-fold) was statistically
significant (p,0.001) in both cases. Taken together that cleavage
of cystatin C by HNE was known to lead to a critically weaker
inhibition (three orders of magnitude) of cathepsin B [29], and that
the CP/CPI imbalance is unchanged in both Ps+ and Ps2 groups,
results also support that cystatin C may be protected from the
harmful activity of HNE in CF expectorations. On the other hand
the CP/CPI imbalance is smaller than that in BALF from patients
with acute infiltrative inflammatory disorders (CP/CPI balance: 3-
to 5-fold), due to the concentration of active CPs being lower in
CF sputum. These data indicated that cathepsin activities are out
of control in chronic inflammation disorders, which supports the
hypothesis that CPs take part in the degradation and remodeling
of major ECM and BM components that are associated with the
progression of the disease. But the exact contributions of individual
cathepsins to the pathophysiology of CF remain unclear [16].
However our use of a standardized procedure in which
proteolytic activities are expressed with reference to the protein
content of each sample (nmole/g) confirms that HNE is a valuable
marker of infection by P. aeruginosa (P,0.01), regardless of the
method used. Our data also indicate that cathepsin activities may
not be used as a reliable indicator of bacterial colonization and
Pseudomonas infection, unlike a previous proposal [18]. Although it
is well established that increased clearance promotes an influx of
cells, which may increase the protein concentration in the sputum,
these contradictory results underline that our qualitative analysis
are not expressed with reference to sputum sample volume (or
weight), which can vary during specimen collection.
Zymogen activation
High-Mr forms of extracellular cathepsin B, corresponding to a
stable, noncovalent complex between cathepsin B and its 6-kDa
propeptide, have been found in the media of mammary tumor
explants and in purulent sputum from patients with bronchiectasis,
an obstructive lung disease like emphysema and cystic fibrosis,
with impaired clearance of mucous secretions [40]. Breakdown of
the inhibitory propeptide resulted in increased enzymatic activity,
indicating that extracellular stabilized cathepsin B can be
dormant. We detected no such complexes in CF sputum, but we
Figure 2. Degradation of human HMWK by CF sputum.
Exogenous HMWK was incubated in the activity buffer with superna-
tants of CF sputum at 30uC for 0–5 hours. Hydrolysis products were
separated by 12.5% SDS-PAGE, transferred to nitrocellulose membranes
and immunoblotted with rabbit polyclonal anti-kininogen antibody
[24]. Lane 1, 0-h incubation; lane 2, 2-h incubation; lane 3, 5-h
incubation; lane 4, 5-h incubation in the presence of CA-074; lane 5, 5-h
incubation in the presence of E-64. For clarity, one representative
sample is shown.
doi:10.1371/journal.pone.0025577.g002
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procathepsins B, L and S (Figure 1). Thus the presence of acid
oligosaccharides at cell surfaces [41] and the local acidic micro-
environnements in CF epithelial lining fluids [16] should lead to
weaker interactions between the proregion and the catalytic
domain, which may favor the autoproteolytic conversion to
mature active cathepsins (for review: [42]). We investigated the
in vitro activation of procathepsins B and S by incubating CF
sputum under acidic conditions (Figure 4A). The two procathep-
sins had similar maturation patterns, and both were abolished by
E-64 (data not shown). The band corresponding to the mature
protease intensified and became maximal at 5 hours. The
autocatalytic processing of cathepsin B led to the release of the
,24/25 kDa (double-chain), but not the ,31 kDa form, as
mainly observed in CF sputum (Figure 1). This was associated with
a relatively small (,1.6-fold) increase in proteolytic activity against
AMC peptides, due to the concomitant time-dependent inactiva-
tion of cysteine cathepsins at 37uC. The quiescent procathepsins in
CF sputum correspond to an activateable proteolytic reserve that
may strengthen the CP/CPI imbalance and promote the
deleterious elastinolytic and collagenolytic activities of cathepsins,
especially during exacerbation episodes. This is in contrast to the
situation in samples from patients with silicosis [6]. Incubation of
CF sputum at a weakly basic pH also led to the proteolytic release
of cathepsin B (,31 kDa; the single-chain form). Immunoblotting
also showed that the rate and yield of activation were much
greater in Ps+ sputum than in Ps2 CF sputum (Figure 4B), while
the processing of procathepsin B was impaired by Pefabloc, an
irreversible serine protease inhibitor. Taken together that HNE
activity in Ps+ CF sputum was significantly higher than in the Ps-
CF sputum and a former report by Buttle et al. [43], the present
observation supports that HNE may possibly process procathepsin
B to its active form. However, our data also suggest that a such
serine protease-dependent maturation of cathepsin B probably
does not occur primarily in either P. aeruginosa-positive or P.
aeruginosa-negative CF sputum, since the major band detected by
immunoblotting and active-site labeling corresponded to the
double-chain cathepsin B.
In conclusion, we identified active cathepsins B, H, K, L and S
in sputum from CF patients, as well as proforms that may be
processed autocatalytically or possibly by elastase (cathepsin B), in
agreement with the overproduction and secretion of cysteine
cathepsins in chronic lung inflammatory diseases [44]. We also
found that kininogens, their natural circulating inhibitors, are
extensively degraded. Thus the overall imbalance between
cysteine proteases and related inhibitors favors the uncontrolled
proteolytic activities of cathepsins. These uncontrolled cathepsins
could then contribute to the pathophysiological breakdown/
Figure 3. CP and HNE activities, and CP/CPI balance in CF sputum. (+): P. aeruginosa-colonized CF sputum; (2): P. aeruginosa-negative CF
sputum. Cathepsins B, H, K, L and S and HNE activities were quantified as reported in details in the experimental section. Data are shown as individual
points and statistically significant P values are shown. The horizontal bars indicate medians. (A) Cathepsins B, L, S, K and H. (B) CP/CPI balance. CPI:
expressed as inhibitory site (cystatin-like) equivalent. (C) Elastase activities: the horizontal bars indicate medians. The western blot analysis was
performed using a rabbit anti-HNE antibody (representative samples are shown). b, unbound HNE; w, bound HNE.
doi:10.1371/journal.pone.0025577.g003
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cystic fibrosis. Cathepsins also seem play a critical role in the
regulation of the antimicrobial activity of innate immunity proteins
in cystic fibrosis, thus favoring the colonization by pathogens like
P. aeruginosa, and infection. Cysteine cathepsins cleave beta-
defensins, lactoferrin, and secretory leukocyte protease inhibitor
and abrogate their microbicidal activity [44]. However we
observed no significant difference in the CP activities and CP/
CPI imbalance of P. aeruginosa-positive samples and P. aeruginosa-
negative samples. Hence the cathepsin activities cannot be used as
an indicator of colonization by this pathogen in CF patients.
Unlike neutrophil elastase, human cathepsins are not consistent
markers of infection by P. aeruginosa in CF patients.
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